Pharmaceuticals News and Research

RSS

Doctoral students of Magicbullet network to develop 'gentle' cancer treatment

Medication that specifically targets cancer cells and delivers its active agent without harming healthy cells - this is what doctoral students of the Magicbullet network will be working on from mid-2015. Bielefeld University is coordinating the programme for the development of "gentle" cancer treatment.

19 Feb 2015

Pioneering Separations Company Quad Technologies Set To Revolutionize Cell Isolation Following Successful Investment

Quad Technologies Inc (“Quad”), developer of a novel separation technology, has formally announced its entry into the cell separation market.

19 Feb 2015

Novasep selected to commercially biomanufacture Celladon's Mydicar API

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces that it has entered into an agreement with Celladon, a clinical-stage biotechnology company. Novasep will prepare to supply the drug substance for MYDICAR®.

19 Feb 2015

Particle sciences manufactures clinical supplies for Kinex’s glioblastom therapeutic

Particle Sciences, Inc (PSI), has completed the manufacturing of clinical supplies for the first in human studies of KX2-361 (KX02), Kinex Pharmaceuticals’ small molecule Src/pre-tublin inhibitor.

19 Feb 2015

UT Dallas study reports new gene therapy approach

Bioengineers at The University of Texas at Dallas have created a novel gene-delivery system that shuttles a gene into a cell, but only for a temporary stay, providing a potential new gene-therapy strategy for treating disease.

19 Feb 2015

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Nicotine's primary metabolite supports learning and memory by amplifying the action of a primary chemical messenger involved in both, researchers report.

19 Feb 2015

Weill Cornell receives NIH grant to study TB-causing bacteria

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration among six institutions in close alliance with voluntary pharmaceutical partners.

19 Feb 2015

Researchers assemble comprehensive map of human epigenome

Virtually every cell in the body carries an identical genome. But how is it possible that each of the body's 200 different types of specialized cells - in the heart, brain, bone, skin and elsewhere - develops from the same DNA instruction book?

19 Feb 2015

Excellere Partners completes sale of U.S. Water Services to Allete

Excellere Partners, a Denver-based private equity firm focused on partnering with middle-market entrepreneurs and management teams, announced today that it completed the sale of its portfolio company U.S. Water Services, Inc., to Allete on February 10, 2015.

19 Feb 2015

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the all new InspiraChamber Anti-Static Valved Holding Chamber (VHC) under a strategic licensing agreement with the New Jersey based respiratory research and development company InspiRX Inc.

19 Feb 2015

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2014, including a summary of recent corporate highlights.

19 Feb 2015

Midwest Compassion Center, Dr. Alan Shackelford join forces to treat epilepsy through medical cannabis

Midwest Compassion Center and Dr. Alan Shackelford join forces in the fight to treat epilepsy through the use of medical cannabis at their Will County dispensary. With growing concerns over the potentially negative side effects of pharmaceuticals and their inability to provide adequate symptom control in as many as 30% of patients with seizures, Dr. Shackelford and MCC will collaborate on research with the goal of developing new treatment options for patients dealing with a debilitating illness or condition, including seizures.

19 Feb 2015

PAREXEL International expands clinical trial site alliance network

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations (SMOs) that enables PAREXEL to quickly access and enroll patient populations for clients' clinical trials worldwide.

From Parexel 18 Feb 2015

First comprehensive maps and analyses of human epigenomes revealed

Two dozen scientific papers published online simultaneously on Feb. 18, 2015 present the first comprehensive maps and analyses of the epigenomes of a wide array of human cell and tissue types. Epigenomes are patterns of chemical annotations to the genome that determine whether, how, and when genes are activated.

18 Feb 2015

UT Southwestern researchers find that acetate speeds up growth and metastasis of tumors

UT Southwestern Medical Center researchers seeking novel ways to combat cancer found that giving acetate, a major compound produced in the gut by host bacteria, to mice sped up the growth and metastasis of tumors.

18 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

From the scent of geranium to cough medicine; A self-assembling catalyst helps to construct complex biological scaffolds

With great elegance nature builds up complex structures from simple building blocks. A central class of compounds are terpenes. More than 8000 terpenes and about 30,000 of the related terpenoids are currently known. They are the key substances for many biological and pharmaceutical functions.

18 Feb 2015

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Scientists at Trinity College Dublin have uncovered a marvel molecule that blocks a key driver of inflammatory diseases. The finding could meet a major unmet clinical need by inspiring new non-invasive treatments for arthritis, multiple sclerosis and Muckle-Wells syndrome, among a myriad of other inflammatory diseases.

18 Feb 2015

Innophos Holdings' net sales decrease 1% to $194 million in fourth quarter 2014

Innophos Holdings, Inc., a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets, today announced its financial results for the fourth quarter and full year 2014.

18 Feb 2015

Biotech investor invests in InterCure to increase stake in XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.

17 Feb 2015

Pharmaceuticals News and Research

Doctoral students of Magicbullet network to develop 'gentle' cancer treatment

Pioneering Separations Company Quad Technologies Set To Revolutionize Cell Isolation Following Successful Investment

Novasep selected to commercially biomanufacture Celladon's Mydicar API

Particle sciences manufactures clinical supplies for Kinex’s glioblastom therapeutic

UT Dallas study reports new gene therapy approach

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Weill Cornell receives NIH grant to study TB-causing bacteria

Researchers assemble comprehensive map of human epigenome

Excellere Partners completes sale of U.S. Water Services to Allete

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Regulus Therapeutics reports net loss of $22.2 million for fourth quarter 2014

Midwest Compassion Center, Dr. Alan Shackelford join forces to treat epilepsy through medical cannabis

PAREXEL International expands clinical trial site alliance network

First comprehensive maps and analyses of human epigenomes revealed

UT Southwestern researchers find that acetate speeds up growth and metastasis of tumors

Actavis provides overview of standalone global pharmaceutical development pipeline

From the scent of geranium to cough medicine; A self-assembling catalyst helps to construct complex biological scaffolds

Trinity scientists reveal new marvel molecule that can block key process in inflammatory diseases

Innophos Holdings' net sales decrease 1% to $194 million in fourth quarter 2014

Biotech investor invests in InterCure to increase stake in XTL Biopharmaceuticals

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring